Whittier Trust Co Has Decreased Johnson & Johnson Com (JNJ) Position, Bio-Rad Laboratories, Inc. (BIO) Had 2 Bulls

June 20, 2017 - By Clifton Ray

Among 3 analysts covering Bio-Rad Laboratories (NYSE:BIO), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Bio-Rad Laboratories had 8 analyst reports since August 7, 2015 according to SRatingsIntel. Jefferies maintained the stock with “Buy” rating in Wednesday, April 12 report. CL King initiated the stock with “Buy” rating in Thursday, October 13 report. The company was maintained on Friday, April 28 by Jefferies. Jefferies maintained it with “Buy” rating and $225 target in Wednesday, September 7 report. See Bio-Rad Laboratories, Inc. (NYSE:BIO) latest ratings:

28/04/2017 Broker: Jefferies Rating: Buy New Target: $250.00 Maintain
12/04/2017 Broker: Jefferies Rating: Buy New Target: $250.00 Maintain
18/01/2017 Broker: Deutsche Bank Rating: Hold New Target: $195.00 Initiates Coverage On

Whittier Trust Co decreased Johnson & Johnson Com (JNJ) stake by 1.91% reported in 2016Q4 SEC filing. Whittier Trust Co sold 7,245 shares as Johnson & Johnson Com (JNJ)’s stock rose 6.85%. The Whittier Trust Co holds 371,983 shares with $42.86M value, down from 379,228 last quarter. Johnson & Johnson Com now has $364.72B valuation. The stock decreased 0.21% or $0.28 during the last trading session, reaching $134.07. About shares traded. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since June 20, 2016 and is uptrending. It has underperformed by 4.16% the S&P500.

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on July, 18. They expect $1.78 earnings per share, up 2.30% or $0.04 from last year’s $1.74 per share. JNJ’s profit will be $4.84 billion for 18.83 P/E if the $1.78 EPS becomes a reality. After $1.83 actual earnings per share reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts -2.73% negative EPS growth.

Since February 1, 2017, it had 0 insider purchases, and 5 insider sales for $14.98 million activity. 16,299 shares were sold by Pruden Gary J, worth $1.99M on Tuesday, February 28. The insider Kapusta Ronald A sold $1.78M. Another trade for 50,000 shares valued at $6.18 million was made by Duato Joaquin on Friday, March 3. Shares for $2.58M were sold by Stoffels Paulus on Wednesday, February 15. Ullmann Michael H sold $2.45M worth of stock.

Investors sentiment increased to 0.94 in Q4 2016. Its up 0.12, from 0.82 in 2016Q3. It increased, as 63 investors sold JNJ shares while 834 reduced holdings. 114 funds opened positions while 731 raised stakes. 1.72 billion shares or 0.88% more from 1.71 billion shares in 2016Q3 were reported. Orleans Cap Mgmt Corporation La stated it has 23,416 shares or 1.93% of all its holdings. Puplava Fin holds 0.14% in Johnson & Johnson (NYSE:JNJ) or 1,899 shares. Guardian Investment Mgmt, a California-based fund reported 33,709 shares. Guyasuta Investment Advsrs Incorporated reported 3.43% in Johnson & Johnson (NYSE:JNJ). Roanoke Asset New York holds 0.14% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 2,700 shares. Profund Advisors Lc holds 159,487 shares. The Virginia-based Signature Financial Management Inc has invested 0.31% in Johnson & Johnson (NYSE:JNJ). Destination Wealth has 182,957 shares. 76,936 were accumulated by Keating Counselors. Cg Asset Limited Company has 1.79% invested in Johnson & Johnson (NYSE:JNJ) for 41,629 shares. Todd Asset Limited Liability Corp stated it has 0.02% in Johnson & Johnson (NYSE:JNJ). Marco Inv Limited Liability Company reported 1.17% of its portfolio in Johnson & Johnson (NYSE:JNJ). The California-based Ep Wealth Advsrs Inc has invested 1.64% in Johnson & Johnson (NYSE:JNJ). Comgest Sas reported 3.49% in Johnson & Johnson (NYSE:JNJ). Lee Danner And Bass accumulated 1.5% or 111,071 shares.

Whittier Trust Co increased Spdr Msci Acwi X U.S. (CWI) stake by 27,767 shares to 262,226 valued at $8.26M in 2016Q4. It also upped Ishares National 0 (SUB) stake by 3,969 shares and now owns 13,079 shares. Ishares S&P National Munis Amt (MUB) was raised too.

Among 16 analysts covering Johnson & Johnson (NYSE:JNJ), 8 have Buy rating, 1 Sell and 7 Hold. Therefore 50% are positive. Johnson & Johnson had 44 analyst reports since August 7, 2015 according to SRatingsIntel. The company was downgraded on Thursday, January 26 by Wells Fargo. The rating was maintained by Jefferies on Tuesday, March 15 with “Hold”. Argus Research upgraded Johnson & Johnson (NYSE:JNJ) on Wednesday, July 20 to “Buy” rating. The stock has “Hold” rating by Jefferies on Friday, June 16. The stock of Johnson & Johnson (NYSE:JNJ) earned “Outperform” rating by RBC Capital Markets on Wednesday, July 20. The rating was initiated by Societe Generale on Wednesday, April 6 with “Hold”. The stock of Johnson & Johnson (NYSE:JNJ) earned “Neutral” rating by Atlantic Securities on Friday, December 18. On Wednesday, October 7 the stock rating was maintained by RBC Capital Markets with “Outperform”. The stock of Johnson & Johnson (NYSE:JNJ) has “Outperform” rating given on Wednesday, January 25 by RBC Capital Markets. The firm has “Equal-Weight” rating given on Tuesday, November 29 by Barclays Capital.

Bio-Rad Laboratories, Inc. is a maker and distributor of its life science research and clinical diagnostics products. The company has market cap of $6.66 billion. The Firm operates through two divisions: Life Science and Clinical Diagnostics. It has a 237.35 P/E ratio. It makes and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

The stock increased 2.00% or $4.42 during the last trading session, reaching $225.03. About shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 53.78% since June 20, 2016 and is uptrending. It has outperformed by 37.08% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: